Enrico Tedeschini

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: a meta-analysis
    Enrico Tedeschini
    Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Eur Neuropsychopharmacol 20:562-7. 2010
  2. doi Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach
    Enrico Tedeschini
    Depression Clinical and Research Program, Harvard Medical School, Massachusetts General Hospital, 50 Staniford St, Boston, MA 02114, USA
    J Clin Psychiatry 72:98-113. 2011
  3. doi Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants
    Marlene P Freeman
    Perinatal and Reproductive Psychiatry Program, Massachusetts General Hospital, 185 Cambridge St, 2nd Floor, Boston, MA 02114, USA
    J Clin Psychiatry 71:682-8. 2010
  4. doi Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials
    Nadia Iovieno
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 72:1144-51. 2011
  5. ncbi Does the frequency of follow-up assessments affect clinical trial outcome? A meta-analysis and meta-regression of placebo-controlled randomized trials
    Nadia Iovieno
    Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Int J Neuropsychopharmacol 15:289-96. 2012
  6. doi Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials
    Nadia Iovieno
    Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Int Clin Psychopharmacol 26:69-74. 2011
  7. doi Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis
    Paola Pedrelli
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 31:582-6. 2011
  8. doi Severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors
    George I Papakostas
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Eur Neuropsychopharmacol 22:347-55. 2012
  9. doi Adjunctive pregabalin in partial responders with major depressive disorder and residual anxiety
    Mario Vitali
    Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy
    J Clin Psychopharmacol 33:95-8. 2013

Collaborators

Detail Information

Publications9

  1. doi Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: a meta-analysis
    Enrico Tedeschini
    Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Eur Neuropsychopharmacol 20:562-7. 2010
    ..An increased likelihood of receiving placebo did not inflate discontinuation rates which did not influence the degree of antidepressant-placebo "separation"...
  2. doi Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach
    Enrico Tedeschini
    Depression Clinical and Research Program, Harvard Medical School, Massachusetts General Hospital, 50 Staniford St, Boston, MA 02114, USA
    J Clin Psychiatry 72:98-113. 2011
    ..In order to accomplish this, we examined the relationship between a "positive" or "negative" finding early on (weeks 1-4), and outcome at end point...
  3. doi Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants
    Marlene P Freeman
    Perinatal and Reproductive Psychiatry Program, Massachusetts General Hospital, 185 Cambridge St, 2nd Floor, Boston, MA 02114, USA
    J Clin Psychiatry 71:682-8. 2010
    ....
  4. doi Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials
    Nadia Iovieno
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 72:1144-51. 2011
    ....
  5. ncbi Does the frequency of follow-up assessments affect clinical trial outcome? A meta-analysis and meta-regression of placebo-controlled randomized trials
    Nadia Iovieno
    Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Int J Neuropsychopharmacol 15:289-96. 2012
    ....
  6. doi Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials
    Nadia Iovieno
    Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Int Clin Psychopharmacol 26:69-74. 2011
    ..placebo) in this population as they are in the general MDD population. Higher general response rates observed in the co-morbid MDD population are intriguing, and require replication...
  7. doi Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis
    Paola Pedrelli
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 31:582-6. 2011
    ..Future studies examining the effectiveness of antidepressants while controlling for several variables such as psychosocial treatment and assessing the specific classes of antidepressants are needed...
  8. doi Severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors
    George I Papakostas
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Eur Neuropsychopharmacol 22:347-55. 2012
    ..These findings are preliminary, of yet undetermined clinical relevance, and warrant replication and further exploration...
  9. doi Adjunctive pregabalin in partial responders with major depressive disorder and residual anxiety
    Mario Vitali
    Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy
    J Clin Psychopharmacol 33:95-8. 2013
    ..Anxiety symptoms in depression result often in treatment resistance, residual symptoms, and persistent functional impairment...